ABSTRACT: Most pheochromocytomas/paragangliomas should be evaluated with anatomical imaging (computed tomography or magnetic resonance imaging) followed by functional imaging (nuclear medicine modalities). Functional imaging assures that the tumor is indeed a pheochromocytoma/paraganglioma and enables more thorough localization, especially detecting as many lesions as possible (in particular for metastatic disease). Functional imaging for pheochromocytomas/ paragangliomas, can use radiolabled ligands specific for pathways of synthesis, metabolism, and inactivation of catecholamines or nonspecific ligands. In an overview of the available nuclear medicine modalities, we summarize the accumulated experience and recommend when functional imaging should be applied to patients with pheochromocytoma/paraganglioma.
INTRODUCTION
Although pheochromocytomas are predominantly sporadic, about 24% of patients with apparent sporadic pheochromocytoma may be carriers of germline mutations that entail a predisposition for extra-adrenal and often multifocal disease.
1 About 26-35% of these tumors are metastastic, [2] [3] [4] [5] and about 10% present with metastatic disease at initial diagnosis. 6 In the context of the clinical evaluation of pheochromocytoma/paraganglioma, anatomical imaging with computed tomography (CT) or magnetic resonance (MR) should be done in all patients. After anatomical imaging is performed, functional (nuclear medicine) modalities are used to prove that the tumor is indeed pheochromocytoma/paraganglioma, as well as to detect as many lesions as possible (for metastatic disease) and to choose the appropriate therapeutic plan. Nuclear medicine modalities can be categorized into those that are specific for the catecholamine synthesis/secretion pathway and those that are nonspecific, that is, they reflect other aspects of tumor pathophysiology.
Most pheochromocytoma/paraganglioma cells (chromaffin cells) are distinguished from other tumor cells in that they express the norepinephrine transport system (hNET). 7 The latter is responsible for the uptake of norepinephrine and epinephrine from the synaptic cleft into the presynaptic neuron of the sympathetic nervous system. hNET thus not only terminates neural transmission by removal of the neurotransmitter norepinephrine but also enables specific functional imaging. In this manuscript we will review the results of imaging of pheochromocytoma obtained with various radiotracers. We begin by describing several radiotracers that depend upon hNET for transport to pheochromocytoma cells followed by tracers whose uptake and retention are independent of hNET (FIG. 1) .
SPECIFIC FUNCTIONAL IMAGING
Attempts to image pheochromocytoma by specific radiotracer techniques began with the development of meta-iodobenzylguanidine (m-IBG) by Wieland and colleagues at the University of Michigan. 8 Sisson and colleagues reported successful localization of pheochromocytomas using m-IBG. 9 Initially, m-IBG was labeled with iodine-131. m-IBG labeled with iodine-123 has become more common because of the characteristics of I-123, which makes it a better radiolabel than iodine-131 for diagnostic evaluation of pheochromocytoma. Relative to I-131, I-123 has a shorter half-life (13.2 h vs. 8 days), a principal emission photon energy much closer to the 140 kEv of Tc-99m, around which gamma cameras are designed (159 kEv I-123 vs. 364 kEv I-131), and lack of beta particulate emission, which adds to the radiation burden and limits the activity that can be administered. Because of the higher emitted photon flux, I-123 m-IBG images contain about tenfold the number of acquired counts as do those obtained with I-131 m-IBG; they are of much higher quality; and tomographic images (SPECT -single photon emission computed tomography) can be obtained for further localization (FIG. 2) . m-IBG is useful in localizing pheochromocytomas in any part of the body. It is especially valuable in localizing extra-adrenal sites of pheochromocytoma, and pheochromocytoma in areas of the body previously operated upon, where anatomic imaging is compromised by distortion of anatomy and the presence of metallic clips that degrade anatomic-based images. a-IBG (aminoiodobenzylguanidine) was synthesized as a kit-based formula that would allow local production of the radiolabeled compound. 10 Although pheochromocytomas were readily identified using this compound, lung accumulation of a-IBG was higher than that of m-IBG. Positron emission tomography (PET) tracers present some advantages compared with single photon-emitting tracers. PET tracers utilize PET cameras, which inherently produce tomographic images with higher spatial resolution than conventional scintigraphic imaging. PET tracers utilize shorter-lived isotopes, enabling higher doses to be administered for a similar radiation exposure. Because of the short half-life, tracers that reflect different aspects of tumor biology could be administered in a single session.
The first positron-emitting tracer of the sympathetic nervous system suitable for administration in humans was m-hydroxyephedrine (HED). HED was designed to image the sympathetic innervation of the heart. Structurally, it resembles norepinephrine but is not susceptible to intracellular degradation by the enzyme monoamine oxidase. m-HED was shown to accumulate in myocardium by transport by the human norepinephrine transporter (hNET). It was labeled with the positron emitter, carbon-11. C-11 has a half-life of only 20 min, thus C-11 HED requires onsite synthesis as its short half-life precludes widespread distribution. Shulkin and colleagues showed that outstanding functional images of pheochromocytomas could be obtained using C-11 HED and a PET camera (FIG. 2) . 11 Pheochromocytomas were localized in 9 of 10 patients with pheochromocytoma. High-quality functional images were acquired within minutes of injection, and tumor to nontumor ratios were more favorable than those of I-123 m-IBG. Trampal and colleagues have also reported excellent results with C-11 HED. 12 Because of the need for onsite synthesis, few centers have access to this compound and it is not yet widely utilized.
Closely related to the endogenous neurotransmitter norepinephrine is the catecholamine epinephrine. Like HED, epinephrine is labeled with C-11, requiring onsite synthesis. Unlike HED, epinephrine is a substrate for the catecholamine catabolic enzymes COMT (catechol-O-methyltransferase) and MAO (monoamine oxidase), and thus its retention in myocardium requires intact catecholamine storage vesicles. The majority of pheochromocytomas can be visualized using C-11 epinephrine. 13 However, the rate of successful localization is less than that of m-IBG, and it is not likely that C-11 epinephrine will replace m-IBG for functional imaging of pheochromocytoma. As with C-11 HED, uptake occurs quite rapidly and is sustained through the imaging period.
Another PET ligand that targets steps of catecholamine synthesis is F-18-fluorodopamine (F-18-DA) (FIG. 3) . PET with F-18-DA was performed in 18 patients with metastatic pheochromocytoma and was compared to planar I-131-m-IBG scintigraphy. F-18-DA was superior to I-131-m-IBG: it localized pheochromocytomas in all patients and showed numerous foci that were not imaged with I-131-m-IBG scintigraphy.
14 In more recent studies, PET with F-18-DA was superior to I-123-m-IBG scintigraphy in imaging adrenal and/or benign pheochromocytomas and paragangliomas (Pacak et al., unpublished data). 15 Fluorodopa was developed to image the dopaminergic elements of the central nervous system. More recently it has been shown to provide functional images of pheochromocytoma. In 14 patients, 17 sites of pheochromocytoma were identified both by MRI and PET F-18 fluorodopa imaging. 16 In 4 patients, m-IBG scintigraphy was falsely negative. F-18 fluorodopa is presumably converted into fluorodopamine and then transported into pheochromocytomas by hNET, although the large neutral amino acid transporter may also contribute.
NONSPECIFIC FUNCTIONAL IMAGING
FDG (18-fluorodeoxyglucose) is used for the detection and management of many types of tumors in children and adults. FDG portrays the glucose metabolic activity of tumors, and its uptake and retention are unrelated to catecholamine uptake and storage. FDG is now widely available commercially. The first report of FDG uptake in pheochromocytoma involved two patients whose pheochromocytomas did not accumulate mIBG. Further studies showed that most benign and most malignant pheochromocytomas could be localized with FDG PET.
17 FDG PET appears particularly valuable for the localization of pheochromocytomas that do not accumulate m-IBG or other tracers of the sympathetic nervous system. [17] [18] [19] Somatostatin receptor scintigraphy is of limited value in the localization of pheochromocytoma. Both pheochromocytomas and paragangliomas express somatostatin receptors. [20] [21] [22] The octapeptide octreotide is an analogue of somatostatin that is chelated with diethylenetriaminepentaacetate (DTPA) and labeled with indium-111 for diagnostic imaging. We have not found it useful in the evaluation of pheochromocytomas in the abdomen because of its normal intense accumulation in the liver, spleen, and kidneys, and excretion into the gastrointestinal tract. It might be useful for identifying malignant/metastatic pheochromocytomas or paragangliomas; [23] [24] [25] [26] [27] [28] [29] such malignant/metastatic tumors can be candidates for radiolabeled somatostatin analogue therapy.
NEWER FUNCTIONAL IMAGING LIGANDS
Newer potential functional imaging modalities specific for pheochromocytomas/paragangliomas include PET with F-18-fluorobenzylguanidine. 30 New somatostatin receptor ligands, which are yet to be evaluated clinically, for SPECT 31 or PET [32] [33] [34] [35] [36] [37] have been developed (they are nevertheless nonspecific for pheochromocytomas/paragangliomas).
RECOMMENDATIONS AND PERSPECTIVES
In conclusion, regarding clinical practice, functional imaging evaluation should be done after anatomical imaging with CT or MRI. Furthermore, we propose that functional imaging be performed in all patients with extra-adrenal, metastatic, or multiple pheochromocytomas, norepinephrinesecreting pheochromocytomas, and epinephrine-secreting adrenal pheochromocytomas larger than 5 cm in diameter. Additionally, functional imaging modalities should be chosen in the postsurgical setting, when biochemical evaluation for pheochromocytoma is inconclusive and in particular when anatomical imaging is negative. Specific functional imaging modalities (m-IBG scintigraphy or PET with 18-F-DA, 18-F-DOPA, or 11-C-HED) are to be used first, and if these turn out to be negative, nonspecific modalities (somatostatin receptor scintigraphy or FDG-PET) should follow.
In future, we anticipate that at centers with PET departments and access to specific PET ligands, most functional imaging procedures for pheochromocytoma/paraganglioma may be PET studies.
